サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1430102

呼吸器感染症診断の世界市場：技術別、プレックス別、場所別、製品別、地域別 - エグゼクティブコンサルタントガイド付き（2024年～2028年）

Respiratory Infection Diagnostic Markets By Technology, Plex, Place, Product and By Region with Executive and Consultant Guides 2024-2028
出版日: | 発行: Howe Sound Research | ページ情報: 英文 602 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.46円
呼吸器感染症診断の世界市場：技術別、プレックス別、場所別、製品別、地域別 - エグゼクティブコンサルタントガイド付き（2024年～2028年）
出版日: 2023年12月18日
発行: Howe Sound Research
ページ情報: 英文 602 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

COVID-19は呼吸器感染症のPOC検査市場を席巻しました。今後市場シェア争いが本格化し、大きな新市場が開かれつつあります。新技術は呼吸器感染症の診断を大きく変えつつあります。結果が出るまでの時間の短縮は、現在の微生物学に基づく診療の何倍もの規模の市場を開いています。検査室はすでに救急室に進出しています。

当レポートは、世界の呼吸器感染症診断市場について調査し、市場の概要とともに、技術別、プレックス別、場所別、製品別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場ガイド

第2章 イントロダクションと市場の定義

第3章 市場概要

  • 市場参入組織
    • 学術研究機関
    • 診断試験開発者
    • 計装サプライヤー
    • 薬品・試薬メーカー
    • 病理サプライヤー
    • 独立系臨床検査室
    • 公共の国立/地域研究所
    • 病院検査室
    • 臨床検査室（POLS）
    • 監査機関
    • 認証機関
  • 呼吸器感染症
  • 診断- 変化する役割
  • COVID-19
  • パンデミックの診断

第4章 市場動向

  • 成長促進要因
  • 成長抑制要因
  • 計測と自動化
  • 診断技術開発

第5章 呼吸器感染症診断の最近の発展

第6章 主要参入企業のプロファイル

  • Abacus Diagnostica
  • Abbott Laboratories
  • Accelerate Diagnostics
  • Access Bio
  • Ador Diagnostics
  • ADT Biotech
  • Akonni Biosystems
  • Altona Diagnostics
  • Alveo Technologies
  • Anatolia Geneworks
  • Antelope Dx
  • Applied BioCode
  • Assurance Scientific Laboratories
  • Aureum Diagnostics
  • Aus Diagnostics
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • Binx Health
  • Biocartis
  • BioFire Diagnostics（bioMérieux）
  • bioMérieux Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Bosch Healthcare Solutions GmbH
  • Celemics
  • Cepheid（Danaher）
  • Chembio
  • Co Diagnostics
  • Credo Diagnostics Biomedical
  • Cue Health
  • Curetis N.V./Curetis GmbH
  • Detect
  • Diagenode Diagnostics
  • Diascopic
  • Diasorin S.p.A.
  • Enzo Biochem
  • Eurofins Scientific
  • Fluxergy
  • Fulgent Genetics
  • Fusion Genomics.
  • Genetic Signatures
  • GenMark Dx（Roche）
  • Hibergene Diagnostics
  • Hologic
  • Immunexpress
  • Inflammatix
  • Invetech
  • Janssen Diagnostics
  • Karius
  • Lexagene
  • LightDeck Diagnostics
  • Luminex Corp
  • Lumos Diagnostics
  • Mammoth Biosciences
  • Maxim Biomedical
  • Meridian Bioscience
  • Mesa Biotech（Thermo Fisher）
  • Millipore Sigma
  • Mindray
  • Mobidiag（Hologic）
  • Mologic
  • Nanomix
  • Operon
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Prenetics
  • Primerdesign（Novacyt）
  • Prominex
  • Qiagen
  • QuantuMDx
  • QuidelOrtho
  • Roche Molecular Diagnostics
  • Seegene
  • Siemens Healthineers
  • Sona Nanotech
  • SpeeDx
  • T2 Biosystems
  • Talis Biomedical
  • Thermo Fisher Scientific Inc.
  • Veramarx
  • Veredus Laboratories
  • Visby Medical
  • XCR Diagnostics
  • Zhejiang Orient Gene Biotech

第7章 世界の呼吸器感染症診断市場

  • 国別の世界市場
  • 技術別の世界市場- 概要
  • プレックス別の世界市場- 概要
  • 場所別の世界市場- 概要
  • 製品別の世界市場- 概要

第8章 世界の呼吸器感染症診断市場- 技術別

  • 微生物学
  • PCR
  • NGS
  • 免疫測定法・その他
  • C19 シングルプレックス

第9章 世界の呼吸器感染症診断市場-プレックス別

  • C19 シングルプレックス
  • シングルプレックス
  • デュプレックス
  • マルチプレックス技術

第10章 世界の呼吸器感染症診断市場- 場所別

  • 病院検査室
  • 外来検査室
  • POC
  • その他

第11章 世界の呼吸器感染症診断市場- 製品別

  • 機器
  • 消耗品
  • ソフトウェアとサービス

第12章 付録

図表

Table of Tables

  • Table 1: Market Players by Type
  • Table 2: Bacterial Causes of Pneumonia
  • Table 3: List of Influenza Pandemics
  • Table 4: Viral Infections of the Respiratory Tract
  • Table 5: Fungal Infections of the Respiratory Tract
  • Table 6: Characteristics of Coronavirus Pandemic Infections
  • Table 7: COVID-19 Symptoms
  • Table 8: Five Factors Driving Growth
  • Table 9: Three Factors Limiting Growth
  • Table 10: Key Diagnostic Laboratory Technology Trends
  • Table 11: Long Term Pathoghen Identification Timetable
  • Table 12: - Global Market by Region
  • Table 13: Global Market by Technology
  • Table 14: Global Market by Plex
  • Table 15: Global Market by Place
  • Table 16: Global Market by Product
  • Table 17: Microbiology by Country
  • Table 18: PCR by Country
  • Table 19: NGS by Country
  • Table 20: Immunoassay/Other by Country
  • Table 21: C19splex by Country
  • Table 22: C19 Single Plex by Country
  • Table 23: Singleplex by Country
  • Table 24: Duplex/Triplex by Country
  • Table 25: Multiplex by Country
  • Table 26: Hospital Lab by Country
  • Table 27: Outpatient Lab by Country
  • Table 28: POC by Country
  • Table 29: Other by Country
  • Table 30: Instruments by Country
  • Table 31: Consumables by Country
  • Table 32: Software & Service by Country
  • Table 33: Laboratory Fee Schedule
  • Table 34: The Most Common Assays
  • Table 35: Largest Revenue Assays

Table of Figures

  • Figure 1: Respiratory Tract Infections
  • Figure 2: The LRI Mortality Rate Globally
  • Figure 3: Global Pandemic Pathogen Status
  • Figure 4: Global Healthcare Spending
  • Figure 5: The Lab Test Pie
  • Figure 6: The Road to Diagnostics
  • Figure 7: The BioFire Respiratory Panel
  • Figure 8: Pneumonia
  • Figure 9: Bacterial Infections of the Respiratory Tract
  • Figure 10: The Development Cycle of Tuberculosis
  • Figure 11: A Flu Epidemic in Europe - Historical Pattern
  • Figure 12: The Single Multiplex Shift
  • Figure 13: Percentage of World Population Over 65
  • Figure 14: Global Market Share Chart
  • Figure 15: Global Market by Technology - Base vs. End Year
  • Figure 16: Global Market by Technology Base Year
  • Figure 17: Global Market by Technology End Year
  • Figure 18: Technology Share by Year
  • Figure 19: Technology Segments Growth
  • Figure 20: Plex - Base vs. End Year Segment Shift
  • Figure 21: Plex Market Base Year
  • Figure 22: Plex Market End Year
  • Figure 23: Plex Share by Year
  • Figure 24: Plex Segments Growth
  • Figure 25: Place - Base vs. End Year
  • Figure 26: Place Market Base Year
  • Figure 27: Place Market End Year
  • Figure 28: Place Share by Year
  • Figure 29: Place Segments Growth
  • Figure 30: Product - Base vs. End Year
  • Figure 31: Product Market Base Year
  • Figure 32: Product Market End Year
  • Figure 33: Product Share by Year
  • Figure 34: Product Segments Growth
  • Figure 35: Microbiology Growth
  • Figure 36: PCR Diagnostics Growth
  • Figure 37: NGS Growth
  • Figure 38: Immunoassay/Other Growth
  • Figure 39: C19splex Growth
  • Figure 40: C19 Single Plex Growth
  • Figure 41: Singleplex Growth
  • Figure 42: Duplex/Triplex Growth
  • Figure 43: Multiplex Growth
  • Figure 44: Hospital Lab Growth
  • Figure 45: Outpatient Lab Growth
  • Figure 46: POC Growth
  • Figure 47: Other Growth
  • Figure 48: Instruments Growth
  • Figure 49: Consumables Growth
  • Figure 50: Software & Service Growth
目次

OVERVIEW:

COVID-19 has broken open the market for point of care testing of respiratory infections. Now the competition for market share begins in earnest. Large new markets are opening up. And lets not forget the screening market, not just for COVID, but for the rest of the 20 something respiratory pathogens as well. Multiplex vs single plex? Explore the rapidly changing market as competitors jockey for position in new markets that are not yet well understood.

New technology is forever changing the diagnosis of respiratory infections. Shrinking time to result is opening up markets multiple times the size of current microbiology based practice. The Laboratory has already moved into the Emergency Room.

The widespread nature of respiratory infections, (young people can get 8 colds a year) means that potential market sizes are enormous. Respiratory, already the largest infectious disease category could multiply in size. This is a growth opportunity for all diagnostic companies. Understand the opportunity and the risk with this in depth report.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1. Market Guides

  • 1.1. Situation Analysis
  • 1.2. Guide for Executives and Business Development Staff
  • 1.3. Guide for Management Consultants and Investment Advisors

2. Introduction and Market Definition

  • 2.1. What are Respiratory Infections?
  • 2.2. The Role of Diagnosis & Treatment
  • 2.3. Market Definition
    • 2.3.1. Revenue Market Size
  • 2.4. Methodology
    • 2.4.1. Methodology
    • 2.4.2. Sources
    • 2.4.3. Authors
  • 2.5. Perspective: Healthcare and the IVD Industry
    • 2.5.1. Global Healthcare Spending
    • 2.5.2. Spending on Diagnostics
    • 2.5.3. Important Role of Insurance for Diagnostics

3. Market Overview

  • 3.1. Players in a Dynamic Market
    • 3.1.1. Academic Research Lab
    • 3.1.2. Diagnostic Test Developer
    • 3.1.3. Instrumentation Supplier
    • 3.1.4. Chemical/Reagent Supplier
    • 3.1.5. Pathology Supplier
    • 3.1.6. Independent Clinical Laboratory
    • 3.1.7. Public National/regional Laboratory
    • 3.1.8. Hospital Laboratory
    • 3.1.9. Physicians Office Lab (POLS)
    • 3.1.10. Audit Body
    • 3.1.11. Certification Body
  • 3.2. Respiratory Infections
    • 3.2.1. Upper vs. Lower - Marketing Implications
    • 3.2.2. Understanding the Role of Pneumonia
    • 3.2.3. Bacterial Infections
      • 3.2.3.1. Streptococcal Infections
      • 3.2.3.2. Acute Otitis Media
      • 3.2.3.3. Bacterial Rhinosinusitis
      • 3.2.3.4. Diphtheria
      • 3.2.3.5. Pneumococcal Pneumonia
      • 3.2.3.6. Haemophilus Pneumonia
      • 3.2.3.7. Mycoplasma Pneumonia (Walking Pneumonia)
      • 3.2.3.8. Chlamydial Pneumonias and Psittacosis
      • 3.2.3.9. Health Care-Associated Pneumonia
      • 3.2.3.10. Pseudomonas Pneumonia
      • 3.2.3.11. Legionnaires Disease
    • 3.2.4. Tuberculosis - A Special Case
    • 3.2.5. Viral Infections
      • 3.2.5.1. The Common Cold
      • 3.2.5.2. Influenza
      • 3.2.5.3. Viral Pneumonia
      • 3.2.5.4. SARS and MERS
      • 3.2.5.5. Measles (Rubeola)
      • 3.2.5.6. Rubella (German Measles)
      • 3.2.5.7. Chickenpox and Shingles
    • 3.2.6. Fungal and Other Pathogens
      • 3.2.6.1. Histoplasmosis
      • 3.2.6.2. Coccidioidomycosis
      • 3.2.6.3. Blastomycosis
      • 3.2.6.4. Mucormycosis
      • 3.2.6.5. Aspergillosis
      • 3.2.6.6. Pneumocystis Pneumonia
      • 3.2.6.7. Cryptococcosis
  • 3.3. Diagnostics - A Changing Role
    • 3.3.1. Historical Practice
    • 3.3.2. Current Diagnostics
    • 3.3.3. The Multiplex Vector
    • 3.3.4. Future Diagnostics - The Question of When and Where
    • 3.3.5. Respiratory Infection Diagnostics - The Destination
    • 3.3.6. Diagnostics as Defensive Weapons
  • 3.4. COVID-19
    • 3.4.1. Signs and symptoms
    • 3.4.2. Transmission
    • 3.4.3. Diagnosis
    • 3.4.4. Prevention
    • 3.4.5. Management
    • 3.4.6. Prognosis
  • 3.5. Pandemic Diagnostics
    • 3.5.1. Risk Management - Spark and Spread
    • 3.5.2. Dx Technology - Nucleic Acid Based
    • 3.5.3. Dx Technology - Immunoassay & Serology
    • 3.5.4. Time to Market and Preparedness Issues
    • 3.5.5. Unrecognized Role of Multiplex in Pandemic Mangement

4. Market Trends

  • 4.1. Factors Driving Growth
    • 4.1.1. Syndromic Multiplexing
    • 4.1.2. T.A.T.
    • 4.1.3. Antimicrobial Resistance Movement
    • 4.1.4. Pandemic Mitigation
    • 4.1.5. An Aging at Risk Population
  • 4.2. Factors Limiting Growth
    • 4.2.1. The Cost Curve
    • 4.2.2. Regulation and coverage
    • 4.2.3. Laissez Faire
  • 4.3. Instrumentation and Automation
    • 4.3.1. The Shrinking Multiplexing Machine
    • 4.3.2. Bioinformatics Networking and Anonymous Reporting
  • 4.4. Diagnostic Technology Development
    • 4.4.1. The Key Role of Time to Result
    • 4.4.2. Single Cell Genomics Changes the Picture
    • 4.4.3. Pharmacogenomics Blurs Diagnosis and Treatment
    • 4.4.4. Pathogen Identification - A Projected Timetable of the Future

5. Respiratory Infection Diagnostics Recent Developments

  • 5.1. Recent Developments - Importance and How to Use This Section
    • 5.1.1. Importance of These Developments
    • 5.1.2. How to Use This Section
  • 5.2. Roche Gets Multiplex Emergency Use Authorization
  • 5.3. ReadyGo Diagnostics, Gemina Labs Pursue Respiratory Market
  • 5.4. 3EO Health to Launch Molecular Point-of-Care Device
  • 5.5. Delve Bio to Commercialize Metagenomic Pathogen Test
  • 5.6. Sensible Diagnostics Nabs Award for Respiratory Panel
  • 5.7. BD - FDA Clearance for Combo Respiratory Test
  • 5.8. Co-Diagnostics Awarded for Upper Respiratory Panel
  • 5.9. FDA Authorizes Cue Health C19 At-Home MDx
  • 5.10. BioMerieux Waiver for Respiratory Mini Panel
  • 5.11. Aptitude Medical Systems Aiming for At-Home Market
  • 5.12. SD Biosensor Eyes Global Expansion For Rapid MDx System
  • 5.13. New bioMerieux Respiratory Diagnostic System
  • 5.14. Visby Medical Nabs FDA EUA for POC Respiratory Panel Test
  • 5.15. SENZO SECURES FUNDING FOR PCR-ACCURATE LATERAL FLOW TEST
  • 5.16. Takara Bio USA, BioExcel Diagnostics Partner for Dx Panels
  • 5.17. ProtonDx's Dragonfly Dx System successfully deployed
  • 5.18. Genomtec Gets CE-IVD Mark for POC Respiratory Disease Test
  • 5.19. FDA Issues First EUA for Non-Prescription COVID-19/Flu/RSV Test
  • 5.20. "Diagnostics for the Real World" Plans Third-Generation POC Platform
  • 5.21. Cue Health Targets DTC Market
  • 5.22. Investors Skeptical of Ortho Clinical Diagnostics Acquisition by Quidel
  • 5.23. Sense Biodetection to Debut Instrument-Free POC MDx
  • 5.24. LGC Develops 'Ultra-High-Throughput' COVID Workflow
  • 5.25. Cue Health Files for IPO for up to $100M
  • 5.26. QuantuMDx Developing Multiplex System, Syndromic Panels
  • 5.27. Bio-Rad Laboratories Gets CE Mark for Respiratory RT-PCR Assay Kit
  • 5.28. BforCure Preparing Multiple Panels for PoC qPCR Platform
  • 5.29. Angstrom Bio Raises $3M in Private Financing
  • 5.30. Test for Them All
  • 5.31. Hologic Banking on MDx Acquisitions
  • 5.32. Pandemic Pushes Handheld qPCR Devices Closer to Commercialization
  • 5.33. Talis Biomedical 2020 Revenues Rise Sharply
  • 5.34. Luminex to Develop Covid/Flu/RSV Test
  • 5.35. Becton Dickinson Charts Transition of COVID Diagnostics
  • 5.36. MiRxes Receives Approval for Multiplex Covid/Flu Test
  • 5.37. New Silicon-Based Test for Infectious Disease Screening
  • 5.38. GenMark to Meet Demand for Respiratory Panel
  • 5.39. Tempus Announces COVID-19 Testing, Data Initiative
  • 5.40. Abacus Diagnostica Readying Multiplex Respiratory Test
  • 5.41. Qiagen Acquires NeuMoDx Molecular
  • 5.42. Companies Shift to Multiplex Tests for SARS-CoV-2, Influenza
  • 5.43. Novacyt Gets CE Mark for Coronavirus, Flu, RSV Combo Panel
  • 5.44. Cepheid Debuts 10-Color Technology With New Tuberculosis Test
  • 5.45. BioMerieux's Pneumonia Panel Could Improve Care
  • 5.46. Mammoth Biosciences Announces CRISPR-Based C19 Diagnostic
  • 5.47. Genetic Signatures Gets CE Mark for C19 Molecular Test
  • 5.48. Qiagen Respiratory Panel with C19 Receives CE Mark
  • 5.49. Lumos Diagnostics Closes $15M Series A Funding
  • 5.50. Fusion Genomics to Assess NGS Respiratory Tract Assay

6. Profiles of Key Players

  • 6.1. Abacus Diagnostica
  • 6.2. Abbott Laboratories
  • 6.3. Accelerate Diagnostics
  • 6.4. Access Bio
  • 6.5. Ador Diagnostics
  • 6.6. ADT Biotech
  • 6.7. Akonni Biosystems
  • 6.8. Altona Diagnostics
  • 6.9. Alveo Technologies
  • 6.10. Anatolia Geneworks
  • 6.11. Antelope Dx
  • 6.12. Applied BioCode
  • 6.13. Assurance Scientific Laboratories
  • 6.14. Aureum Diagnostics
  • 6.15. Aus Diagnostics
  • 6.16. Beckman Coulter Diagnostics
  • 6.17. Becton, Dickinson and Company
  • 6.18. Binx Health
  • 6.19. Biocartis
  • 6.20. BioFire Diagnostics (bioMerieux)
  • 6.21. bioMerieux Diagnostics
  • 6.22. Bio-Rad Laboratories, Inc.
  • 6.23. Bosch Healthcare Solutions GmbH
  • 6.24. Celemics
  • 6.25. Cepheid (Danaher)
  • 6.26. Chembio
  • 6.27. Co Diagnostics
  • 6.28. Credo Diagnostics Biomedical
  • 6.29. Cue Health
  • 6.30. Curetis N.V. / Curetis GmbH
  • 6.31. Detect
  • 6.32. Diagenode Diagnostics
  • 6.33. Diascopic
  • 6.34. Diasorin S.p.A.
  • 6.35. Enzo Biochem
  • 6.36. Eurofins Scientific
  • 6.37. Fluxergy
  • 6.38. Fulgent Genetics
  • 6.39. Fusion Genomics.
  • 6.40. Genetic Signatures
  • 6.41. GenMark Dx (Roche)
  • 6.42. Hibergene Diagnostics
  • 6.43. Hologic
  • 6.44. Immunexpress
  • 6.45. Inflammatix
  • 6.46. Invetech
  • 6.47. Janssen Diagnostics
  • 6.48. Karius
  • 6.49. Lexagene
  • 6.50. LightDeck Diagnostics
  • 6.51. Luminex Corp
  • 6.52. Lumos Diagnostics
  • 6.53. Mammoth Biosciences
  • 6.54. Maxim Biomedical
  • 6.55. Meridian Bioscience
  • 6.56. Mesa Biotech (Thermo Fisher)
  • 6.57. Millipore Sigma
  • 6.58. Mindray
  • 6.59. Mobidiag (Hologic)
  • 6.60. Mologic
  • 6.61. Nanomix
  • 6.62. Operon
  • 6.63. Oxford Nanopore Technologies
  • 6.64. Panagene
  • 6.65. Perkin Elmer
  • 6.66. Prenetics
  • 6.67. Primerdesign (Novacyt)
  • 6.68. Prominex
  • 6.69. Qiagen
  • 6.70. QuantuMDx
  • 6.71. QuidelOrtho
  • 6.72. Roche Molecular Diagnostics
  • 6.73. Seegene
  • 6.74. Siemens Healthineers
  • 6.75. Sona Nanotech
  • 6.76. SpeeDx
  • 6.77. T2 Biosystems
  • 6.78. Talis Biomedical
  • 6.79. Thermo Fisher Scientific Inc.
  • 6.80. Veramarx
  • 6.81. Veredus Laboratories
  • 6.82. Visby Medical
  • 6.84. XCR Diagnostics
  • 6.85. Zhejiang Orient Gene Biotech

7. The Global Market for Respiratory Infection Diagnostics

  • 7.1. Global Market by Country
    • 7.1.1. Table - Global Market by Country
    • 7.1.2. Chart - Global Market by Country
  • 7.2. Global Market by Technology - Overview
    • 7.2.1. Table - Global Market by Technology
    • 7.2.2. Chart - Global Market by Technology - Base/End Year Comparison
    • 7.2.3. Chart - Global Market by Technology - Base Year
    • 7.2.4. Chart - Global Market by Technology - End Year
    • 7.2.5. Chart - Global Market by Technology - Share by Year
    • 7.2.6. Chart - Global Market by Technology - Segment Growth
  • 7.3. Global Market by Plex - Overview
    • 7.3.1. Table - Global Market by Plex
    • 7.3.2. Chart - Global Market by Plex - Base/End Year Comparison
    • 7.3.3. Chart - Global Market by Plex - Base Year
    • 7.3.4. Chart - Global Market by Plex - End Year
    • 7.3.5. Chart - Global Market by Plex - Share by Year
    • 7.3.6. Chart - Global Market by Plex - Segment Growth
  • 7.4. Global Market by Place - Overview
    • 7.4.1. Table - Global Market by Place
    • 7.4.2. Chart - Global Market by Place - Base/End Year Comparison
    • 7.4.3. Chart - Global Market by Place - Base Year
    • 7.4.4. Chart - Global Market by Place - End Year
    • 7.4.5. Chart - Global Market by Place - Share by Year
    • 7.4.6. Chart - Global Market by Place - Segments Growth
  • 7.5. Global Market by Product - Overview
    • 7.5.1. Table - Global Market by Product
    • 7.5.2. Chart - Global Market by Product - Base/End Year Comparison
    • 7.5.3. Chart - Global Market by Product - Base Year
    • 7.5.4. Chart - Global Market by Product - End Year
    • 7.5.5. Chart - Global Market by Product - Share by Year
    • 7.5.6. Chart - Global Market by Product - Segments Growth

8. Global Respiratory Infection Diagnostic Markets - By Technology

  • 8.1. Microbiology
    • 8.1.1. Table Microbiology - by Country
    • 8.1.2. Chart - Microbiology Growth
  • 8.2. PCR
    • 8.2.1. Table PCR - by Country
    • 8.2.2. Chart - PCR Growth
  • 8.3. NGS
    • 8.3.1. Table NGS - by Country
    • 8.3.2. Chart - NGS Growth
  • 8.4. Immunoassay/Other
    • 8.4.1. Table Immunoassay - by Country
    • 8.4.2. Chart - Immunoassay/Other Growth
  • 8.5. C19 Singleplex
    • 8.5.1. Table C19splex - by Country
    • 8.5.2. Chart - C19splex Growth

9. Global Respiratory Infection Diagnostic Markets - by Plex

  • 9.1. C19 Single Plex
    • 9.1.1. Chart - C19 Single Plex Growth
  • 9.2. Singleplex
    • 9.2.1. Table Singleplex - by Country
    • 9.2.2. Chart - Singleplex Growth
  • 9.3. Duplex/Triplex
    • 9.3.1. Table Duplex/Triplex - by Country
    • 9.3.2. Chart - Duplex/Triplex Growth
  • 9.4. Multiplex Technology
    • 9.4.1. Table Multiplex - by Country
    • 9.4.2. Chart - Multiplex Growth

10. Global Respiratory Infection Diagnostic Markets - by Place

  • 10.1. Hospital Lab
    • 10.1.1. Table Hospital Lab - by Country
    • 10.1.2. Chart - Hospital Lab Growth
  • 10.2. Outpatient Lab
    • 10.2.1. Table Outpatient Lab - by Country
    • 10.2.2. Chart - Outpatient Lab Growth
  • 10.3. POC
    • 10.3.1. Table POC - by Country
    • 10.3.2. Chart - POC Growth
  • 10.4. Other Technology
    • 10.4.1. Chart - Other Growth

11. Global Respiratory Infection Diagnostic Markets - by Product

  • 11.1. Instruments
    • 11.1.1. Table Instruments - by Country
    • 11.1.2. Chart - Instruments Growth
  • 11.2. Consumables
    • 11.2.1. Table Consumables - by Country
    • 11.2.2. Chart - Consumables Growth
  • 11.3. Software & Service
    • 11.3.1. Table Software & Service - by Country
    • 11.3.2. Chart - Software & Service Growth

12. Appendices

  • 12.1. United States Medicare System: Clinical Laboratory Fees Schedule
  • 12.2. The Most Used IVD Assays
  • 12.3. The Highest Grossing Assays